Innovator Equity Defined Protection ETF - 6mo Apr/Oct APOC 深 滬
等待開盤 11-06 09:30:00 美东时间
26.0236
+0.074
+0.28%
華盛通- 最 高26.0294
- 今 開25.95
- 成交量 1.84万股
- 最 低 25.96
- 昨 收 25.95
- 總市值 7286.61万
- 52周最高 26.17
- 市盈率 靜 --
- 換手率 0.66%
- 52周最低 24.60
- 委 比 -60.00%
- 總股本 280.00万
- 歷史最高 26.17
- 量 比 1.65
- 振 幅 0.27%
- 歷史最低 24.60
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BD不BD，给个痛快吧
本文来自格隆汇专栏：阿基米德Biotech BD预期已形成堰塞湖。 恒生生物科技指数（HSHKBIO）在节日期间上涨3.7%，重燃创新药二次行情的希望，但在节后...
10-10 08:16
Arrowhead Pharmaceuticals Files To Begin Phase 1/2a Trial for Dual-Target RNAi Drug ARO-DIMER-PA, Aims To Treat Atherosclerotic Cardiovascular Disease From Mixed Hyperlipidemia
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's investigational RNA interference
10-07 19:34
Sanofi To Acquire Rights To Develop, Commercialize Investigational Plozasiran, Arrowhead's RNAi Therapeutic Candidate To Reduce Production Of APOC3 As Potential Treatment For FCS And SHTG, In Greater China
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and
08-01 18:42
华福证券：降脂药行业需求端潜力巨大 多款创新药即将迎来数据催化
多款前沿靶点迎来数据催化，成药性确定性强，建议布局降脂创新药新靶点的国内企业。 智通财经APP获悉，华福证券发布研报称，ASCVD在我国疾病负担日益加重，我国...
01-09 14:33
